A PHASE II STUDY (NCT01883323) EVALUATING THE INFUSION OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES (TIL) AND LOW-DOSE INTERLEUKIN-2 (IL-2) THERAPY FOLLOWING NON-MYELOABLATIVE LYMPHODEPLETION USING CYCLOPHOSPHAMIDE AND FLUDARABINE IN PATIENTS WITH METASTATIC MELANOMA

Marcus Butler1, Linh Nguyen1, Leila Khoja1, David Hogg1, Anthony Joshua1, Bianzheng Zhang1, Norman Franke1, Christine Chen1, Michael Crump1, Danny Ghazarian1, Ayman Al-Habeeb1, Alexandra Easson1, Wey Leong1, David McCready1, Michael Reedijk1, Michael Pniak1, Pei-Hua Yen1, Jessica Nie1, Alisha Elford1, Vinicius Motta1, Diana Gray1, Lisa Wang1, Pamela Ohashi1,2

1Princess Margaret Cancer Centre, Toronto, ON
2Departments of Immunology and Medical Biophysics, University of Toronto, Toronto, ON

The first clinical trial of adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) in Canada is currently accruing at the Princess Margaret Cancer Centre. The trial is a single arm phase II trial in metastatic melanoma, designed to assess safety and response. TILs are expanded ex vivo in an initial culture step, and then further expanded in a “rapid expansion protocol” (REP). On day 14 of the REP, the TILs are harvested for infusion. Patients first receive preparative lymphodepletion with cyclophosphamide (60mg/kg for 2 days) and fludarabine (25mg/m² for 5 days). This is followed by TIL infusion (1x10\(^10\) – 1.6x10\(^11\) cells intravenously) and a moderate dose interleukin-2 (IL-2) regimen (125,000 IU/kg subcutaneous injection, daily for 2 weeks, with 2 days rest between weeks). This dose of IL-2 is lower than what is commonly used in current TIL protocols, with the aim of reducing the significant treatment-limiting toxicity associated with high-dose IL-2 therapy. The trial follows a two-stage Simon design with a maximum target of 12 evaluable patients. To date, eight patients have received investigational treatment. Cell doses ranged from 5.5x10\(^10\) – 1.6x10\(^11\). Response data is pending for the two of the treated patients. For the other patients, the best overall response (RECIST v1.1) was a partial response in two patients and stable disease in four patients. TCR Vβ repertoire analysis of the TIL infusion products suggests that CD8\(^+\) TILs tended to be more oligoclonal than CD4\(^+\) TILs. Immune monitoring demonstrates peripheral oligoclonal expansion select TCR Vβ family subtypes in some patients and indicates that putative regulatory T cells did not markedly expand in peripheral blood following moderate dose IL-2 therapy. Our experience shows that TIL-based trials are feasible at our centre. Accrual will continue and data on safety, clinical responses and immune monitoring will be collected.

Current word count: 281 words in the body (max 300)